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GENETIC DISORDERS – DEVELOPMENT
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Seven novel mutations of the PKD2 gene in families with heterogeneous condition, with at least three genes in-
autosomal dominant polycystic kidney disease. volved: PKD1, which is located in 16p13.3 and which
Background. Autosomal dominant polycystic kidney dis- accounts for the majority of ADPKD cases [2–4]; PKD2,ease (ADPKD) is genetically heterogeneous, with at least three
which is located in 4q21-q22 [5, 6]; and the much rarerchromosomal loci accounting for the disease. Mutations in the
PKD3, which is not yet mapped [7, 8]. The PKD1 andPKD2 gene on the long arm of chromosome 4 are expected
to be responsible for approximately 15% of cases of ADPKD. PKD2 genes have been recently cloned and character-
Methods. We report a systematic screening for mutations ized [9–13].
covering the 15 exons of the PKD2 gene in eight unrelated
Mutation screening in the PKD1 gene has been diffi-families with ADPKD type 2, using the heteroduplex tech-
cult because of its size (cDNA of approximately 14 kb)nique.
Results. Seven novel mutations were identified and charac- and complexity (approximately 75% of the gene is dupli-
terized that, together with the previously described changes, cated). Most of the mutations reported in PKD1 produce
amount to a detection rate of 85% in the population studied. premature translational termination resulting in trun-The newly described mutations are two nonsense mutations,
cated proteins [14–16]. These truncating mutations sug-a 1 bp deletion, a 1 bp insertion, a mutation that involves
gest that ADPKD is caused by the lack of normal protein.both a substitution and a deletion (2511AG→C), a complex
mutation in exon 6 consisting of a simultaneous 7 bp inversion Furthermore, recent evidence of loss of heterozygosity
and a 4 bp deletion, and the last one is a G→C transversion at the PKD1 locus in cystic epithelia has been reported
that may be a missense mutation. Most of these mutations are
[17, 18], suggesting that cystogenesis in ADPKD resultsexpected to lead to the formation of shorter truncated proteins
from the inactivation of the normal copy of the gene bylacking the carboxyl terminus of PKD2. We have also charac-
terized a frequent polymorphism, Arg-Pro, at codon 28 in this a second somatic mutation.
gene. The clinical features of these PKD2 patients are similar The PKD2 gene consists of 15 exons with an open
to the previously described, with the mean age of end-stage reading frame of 2904 bp and a 39UTR of 2086 bp [13,renal disease being 75.5 years (se 6 3.8 years).
19]. Polycystin-2, the PKD2 gene product, is predictedConclusions. Our results confirm that many different muta-
to be a 968-amino acid integral membrane protein withtions are likely to be responsible for the disease and that most
pathogenic defects probably are point or small changes in the six membrane-spanning domains and intracellular amino
coding region of the gene. termini and carboxyl termini. There is a 25 to 30% iden-
tity and a 45 to 50% similarity between PKD2 and either
a 450-amino acid portion of polycystin-1 or a 270 resi-
Autosomal dominant polycystic kidney disease due region of voltage-activated calcium channel a1E-1(ADPKD) is one of the most common Mendelian disor- (VACCa1E-1). The cytoplasmic COOH terminal regionders in humans and the most frequent genetic cause
of polycystin-2 contains a 29-amino acid segment similar
of renal failure in adults [1]. ADPKD is a genetically
to an EF-hand domain. Recent evidence suggests that
the COOH terminus of PKD2 interacts with the coiled-
Key words: PKD2, cysts, ADPKD, gene mutations, heteroduplex. coil domain of PKD1 protein [20, 21]. As the protein
product of the PKD2 gene has homology to a family
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Table 1. Mutations and polymorphism in the PKD2 gene
Mutation Location Nucleotide change Effect on coding sequence Reference
Nonsense:
R306Xa EX4 C→T at 916 Arg→Stop at 306 23
W380X EX5 G→A at 1138 Trp→Stop at 380 13
Q405X EX5 C→T at 1213 Gln→Stop at 405 13
R417Xb EX5 C→T at 1249 Arg→Stop at 417 Present paper
R464Xb EX6 C→T at 1390 Arg→Stop at 464 24
E494X EX6 G→T at 1480 Glu→Stop at 494 23
Q555Xb EX7 C→T at 1663 Gln→Stop at 555 24
Q585Xb EX8 C→T at 1753 Gln→Stop at 585 Present paper
R742X EX11 C→T at 2224 Arg→Stop at 742 13
Y762Xa EX12 C→A at 2286 Tyr→Stop at 762 23
R807Xb EX13 C→T at 2419 Arg→Stop at 807 24
E837Xb EX13 G→T at 2509 Glu→Stop at 837 24
Insertion/deletions:
198insCb EX1 Ins of C at 198 Frameshifting after codon 68 Present paper
534insC EX1 Ins of C at 534 Frameshifting after 180 23
665delGb EX2 Del of G at 665 Frameshifting after 222 24
693insC EX2 Ins of C at 693 Frameshifting after 231 22
972insC EX4 Ins of C at 972 Frameshifting after 325 23
1193delC EX5 Del of C at 1193 Frameshifting after 398 23
1194delAA EX5 Del of 2A at 1194 Frameshifting after 398 23
1362delT EX6 Del of T at 1362 Frameshifting after 455 23
1367inv7 bp EX6 Inv of 7 bp at 1367 and deletion of 4 bp at 1377 Frameshifting after 456 Present paper
–1377 del 4 bpb
1443delTa EX6 Del of T at 1443 Frameshifting after 482 23
1699del4b EX7 Del of 4T at 1699 Frameshifting after 567 24
1781delCa EX8 Del of C at 1781 Frameshifting after 594 23
2151delGb EX11 Del of G at 2151 Frameshifting after 717 24
2152delAb EX11 Del of A at 2152 Frameshifting after 719 Present paper
2152insA EX11 Ins of A at 2152 Frameshifting after 719 38
2511AG→Cb EX13 Subst AG by C at 2511 Frameshifting after 837 Present paper
Splicing:
del 16bp (596212) EX2 Del of 16 bp at 596 212 Splice mutation 23
70911 G→A EX2 G→A at 709 11 Splice mutation 23
71022 A→G EX3 A→G at 710 22 Splice mutation 23
171723 C→G EX8 C→G at 1717 23 Splice mutation 23
224122 A→G EX12 A→G at 2241 22 Splice mutation 23
Missense:
A356Pb EX4 G→C at 1066 Ala→Pro at 356 Present paper
W414G EX5 T→G at 1240 Trp→Gly at 414 23
Polymorphism Location Heterozygosity Nucleotide change Effect on coding sequence Reference
R28P EX1 0.49 G→C at 83 Arg→Pro at 28 Present paper
a Mutation found in two families
b Mutations identified in our sample
Currently, several mutations have been described in for mutations in the PKD2 gene. Seven of them were
the PKD2 gene, and most of them are expected to pro- from Spain (5 from Catalonia and 2 from the center of
duce truncated proteins [13, 22–24] (Table 1). Here we Spain), and one was from Great Britain. A brief clinical
report the identification of seven new mutations in the summary of those in which the mutation was found is
PKD2 gene in unrelated Spanish and British families. shown in Table 2.
To evaluate the renal survival, the age of family mem-
bers whose cause of death was uremia was considered,
METHODS as well as age of end-stage renal disease (ESRD) for
Family description those who died after entering renal replacement therapy.
Autosomal dominant polycystic kidney disease diag-
Mutation screeningnosis was made according to standard criteria [25]. Link-
DNA was prepared from peripheral blood followingage studies were performed with PKD1- and PKD2-
standard procedures. The 15 coding exons of the PKD2linked markers to confirm PKD2 gene segregation in all
of these families [4, 26, 27]. Eight families were screened gene and the associated splice donor and accepted sites
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Table 2. Clinical features of affected family members Survival analysis
Age of Renal Blood The survival time to the onset of ESRD was calculated
Family affected members function SCr pressure through the method of product limit [29].
C-21 72 ESRD at 70 HBP at 68
70, 34 N N
34 N N RESULTS
5 N N
11 N N Mutation screening was performed by heteroduplex
13 N N analysis of PCR products obtained from genomic DNA
C-76 55 ESRD at 53 HBP at 50
and automated DNA sequencing. The whole PKD2 cod-58, 16, 29 N N
C-85 62 N HBP at 50 ing region and all intron/exon boundaries were investi-
52 N HBP at 43 gated in eight probands from unrelated ADPKD families
C-113 72 2 mg/dl HBP at 40
in which linkage of the disease to the PKD2 locus has39, 8, 13 N N
6019 72 ESRD at 68 HBP at 65 been demonstrated. Mutations were found in seven of
58 4 mg/dl HBP at 55 the eight families and are reported in Table 1. Segrega-
43 2 mg/dl HBP at 40
tion of the mutation with the disease in each family was45 N N
6138 55 N HBP tested by either heteroduplex analysis or restriction site
52, 48, 20, 18, 16 N N change.
P326 58 N HBP
32, 26 N N
Nonsense mutations
Abbreviations are: ESRD, end-stage renal disease; HBP, high blood pressure;
N, normal. Two members of family 6138 died with a positive history of intracra- Two nonsense mutations were identified in our sam-
nial aneurysms. ple. In family C21, a 1249C→T transition that substitutes
an arginine for a stop codon at codon 417 (R417X) was
identified in exon 5. This mutation creates a novel DdeI
restriction site in the sequence.were amplified by polymerase chain reaction (PCR) us-
The mutation in family C85 consists of a 1753C→Ting a set of 17 primer pairs described previously [19].
transition in exon 8 that introduces a stop in codon 585Exon 1 is amplified in three overlapping PCR products.
(Q585X). This mutation creates a NheI restriction site.Heteroduplex analysis was performed using Hydrolink
Mutation Detection Enhancement (MDEe) gel solution Mutations causing frameshift
(FMC Bioproducts, Rockland, ME, USA) with the addi-
In family P326, the disease was shown to be caused
tion of 15% (wt/vol) urea, as recommended by the manu- by the insertion of one C in a stretch of 6 Cs (nucleotides
facturer. Briefly, 20 ml of the PCR product were dena- 198 to 203). This mutation (198 ins C) is expected to
tured by heating at 958C for five minutes, were cooled produce a translation frameshift after codon 68 that in-
at 378C, and were then loaded. Gels were typically 25 cm troduces 22 novel amino acids before premature termina-
long and 1.5 mm thick and were run 10 V/cm, stained with tion.
ethidium bromide, and photographed under ultraviolet The mutation in family 6019 consists of a deletion of
light. one A in a stretch of 8 As (nucleotides 2152 to 2159) in
exon 11. This deletion (2152 del A) causes a frameshiftAutomated DNA sequencing and restriction analysis
that introduces 15 novel amino acids.
Automated sequencing of PCR products was per- In family C113, the sequence of exon 13 revealed a
formed on an ABI310 DNA sequencer (Perkin Elmer, mutation involving both substitution and deletion that
Norwalk, CT, USA) using the cycle-sequencing method. affected the dinucleotide AG at position 2511-2 (2511
Sequencing was carried out in both directions with the AG→C). This mutation caused a translation frameshift
exon-specific primers. When a deletion or insertion was that introduced six novel amino acids before premature
suspected, the PCR product was cloned in pMosBlue termination. This mutation produced the loss of a MboII
plasmid vector (Amersham, Arlington Heights, IL, USA) restriction site.
to confirm the mutation by sequencing individual bacte- In family 6138, the sequence of exon 6 revealed a
rial clones. Restriction analysis was performed according complex mutation comprising both a substitution of a 7
to the manufacturer’s instruction. bp (nucleotides from 1367 to 1373) and a 4 bp deletion
(nucleotides 1377 to 1380). The substituted 7 bp stretch
Mutation designation was, in fact, an inversion because the sequence matched
The mutations described in this study were designated that in the complementary original strand. Closer inspec-
following the recommendations of Beaudet and Tsui tion of this region showed two pairs of short complemen-
[28]. Nucleotides and codons were numbered according tary sequences. The repeats of the first one, of 6 bp, are
flanking both the inverted and the deleted sequence, andto the sequence published by Mochizuki et al [13].
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Fig. 1. Complex mutation of family 6138. (A)
Wild-type sequence from nucleotide 1354 to
1388. (B) Mutant sequence found in affected
individuals. The two inverted repeats (6 bp
and 3 bp) flanking the deletion (4 bp, under-
lined) and the inversion (7 bp, boxed) are
indicated in bold. New residues in the mutant
sequence and the premature stop codon are
indicated.
the second pair, of 3 bp, flanks the inverted sequence nosis is also higher with fewer renal cysts present at that
(Fig. 1). The 59 copies of both pairs are together, whereas time than in PKD1. It is unclear if extrarenal complica-
the 39 copies are separated by the deleted sequence. It tions of the disease in PKD2 are less severe than in
is expected that an intracatenary alignment of this pairs PKD1 [4], but liver cysts seem to occur to the same
followed by recombination would simultaneously pro- extent as in PKD1, and a PKD2 family with intracranial
duce the inversion and the deletion. The predicted effect aneurysms has been reported [35]. The clinical features
of this mutation is a frameshift from amino acid 456 with of the patients reported here closely resemble those re-
a premature termination TGA codon after five residues. ported in previous studies [4, 33].
This mutation produces the loss of a DraI restriction In the search for PKD2-causing defects in Spanish and
site. English families, we have identified seven novel muta-
tions in exons 1, 4, 5, 6, 8, 11, and 13 of the PKD2 gene.
Missense mutation Six of them are stop or frameshifting mutations that
The only change observed in family C76 was a are expected to produce truncated products lacking the
1066G→C substitution in exon 4 converting Ala356 to carboxyl terminus of PKD2. They are two nonsense mu-
Pro (A356P). This transversion creates a StuI restriction tations, a 1 bp deletion, a 1 bp insertion, a change
site. To try to determine whether this amino acid change AG→C, and a complex mutation involving both an inver-
is a disease-causing mutation, another 15 unrelated sion and a deletion in exon 6. This complex mutation
PKD2 patients and 100 normal individuals were tested involves exonic sequences that are flanked by short in-
with StuI, and no similar change was observed. verted repeats that might allow the rearrangement to
occur by intracatenary recombination. The clinicalPolymorphism in exon 1
course of the disease in this family is that of typical
Heteroduplex analysis of exon 1 showed a frequent PKD2. Two deceased members exhibited characteristic
polymorphism in several PKD2 patients. It consists of a clinical signs and symptoms as a result of intracranial
83G→C transversion converting Arg28 to Pro (R28P). aneurysms. The expected functional consequence of this
This change creates a BanII restriction site. This poly- mutation is a frameshift translational change with a pre-
morphism was assayed on 15 PKD2 patients and 25 nor- mature termination of protein synthesis. The shortened
mal individuals, and a heterozygosity of 0.49 was de- product would lack the five final transmembrane do-
tected. There was no difference in the frequency of any mains, as well as the carboxyl terminus. Therefore, no
allele between the affected or normal samples. evident relationship could be established between this
mutation and the presence of intracranial aneurysms inSurvival analysis
this family.
The survival analysis, estimated through the method
The seventh mutation is a missense mutation that re-of Kaplan and Meier, showed a mean survival to ESRD
mains to be confirmed as pathogenic. After an extensiveof 75.5 years (se 6 3.8 years; data not shown).
study of the proband of this family (C76) by both hetero-
duplex and single strand conformational polymorphism
DISCUSSION (SSCP) analyses, we only found a change in exon 4,
where a G is replaced by a C at position 1066. ThisMutations in the PKD2 gene are expected to be re-
alteration cosegregates with the disease in the familysponsible for approximately 15% of the cases of polycys-
and is not present in 100 control individuals. The muta-tic kidney disease [3, 4]. The PKD2 disease tends to run
tion results in the substitution of a alanine for a prolinea milder course than the more common PKD1 disease,
at codon 356 of the protein. An alanine at this positionwith longer patient survival and slower progression to-
ward end-stage renal failure [4, 30–34]. The age at diag- is conserved in the murine polycystin-2 [36]. According
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to the predicted model of the PKD2 gene product, ala- molecule to the cell membrane or its binding to other
nine-356 is located in the first extracellular loop. It is components, or the transduction of extracellular signals.
interesting that the only other missense mutation de- Three different structures have been identified in the
scribed so far in this gene (W414G) [23] is also located cytoplasmic end of this protein by computational analysis
in this loop. It is possible that this extracellular loop and/or preliminar in vitro studies. They are an EF-hand
could interact with other molecules or be important for domain that could have Ca21 binding activity and are
the folding of the protein in the membrane. The introduc- encoded by exon 12 of the PKD2 gene [13,19], a region
tion of a proline at this position may disrupt the second- responsible for binding of the coiled-coil domain of
ary structure of the molecule, resulting in a hampered PKD1, which resides in a fragment spanning the last 97
protein function. The proband of this family entered amino acids of PKD2, and an undefined domain that
ESRD at 53 years, an age that can be considered early seems to be implicated in homodimeric interaction with
for this disease. It should be noted that in this study, the PKD2 protein itself [20, 21]. The most carboxy termi-
it has not been determined whether any of the seven nal mutations described so far are in exon 13: 2509G→T
mutations are actually stable post-transcriptionally or [24] and 2511AG→C (discussed in this article).
post-translationally. Even though the number of mutations detected in
No mutation was found in one family with classic PKD2 patients is increasing, it is not possible at this stage
PKD2 and strong familiar evidence of linkage to this to correlate genotype with phenotype. It is imperative to
locus. All coding regions have been studied by hetero- perform multicentric studies in order to establish if there
duplex and SSCA (not shown) analyses in this family, is some kind of correlation between the mutations and
and the results suggest that a mutation could lie in the the clinical features of the patients.
promoter region, or elsewhere in an intron, or could be
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